Literature DB >> 25522000

Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.

Srivalli Telikepalli1, Ozan S Kumru, Jae Hyun Kim, Sangeeta B Joshi, Kristin B O'Berry, Angela W Blake-Haskins, Melissa D Perkins, C Russell Middaugh, David B Volkin.   

Abstract

Upon exposure to shaking stress, an IgG1 mAb formulation in both the liquid and lyophilized state formed subvisible particles. Because freeze-drying was expected to minimize protein physical instability under these conditions, the extent and nature of aggregate formation in the lyophilized preparation were examined using a variety of particle characterization techniques. The effects of formulation variables such as residual moisture content, reconstitution rate, and reconstitution medium were also examined. Upon reconstitution of shake-stressed lyophilized mAb, differences in protein particle size and number were observed by microflow digital imaging, with the reconstitution medium having the largest impact. Shake stress had minor effects on the structure of protein within the particles as shown by SDS-PAGE and FTIR analysis. The lyophilized mAb was shake stressed to different extents and stored for 3 months at different temperatures. Both extent of cake collapse and storage temperature affected the physical stability of the shake-stressed lyophilized mAb upon subsequent storage. These findings demonstrate that physical degradation upon shaking of a lyophilized IgG1 mAb formulation includes not only cake breakage, but also results in an increase in subvisible particles and turbidity upon reconstitution. The shake-induced cake breakage of the lyophilized IgG1 mAb formulation also resulted in decreased physical stability upon storage.
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  IgG; freeze drying/lyophilization; monoclonal antibody; particle size; particles; protein aggregation; proteins; stability

Mesh:

Substances:

Year:  2014        PMID: 25522000      PMCID: PMC4312241          DOI: 10.1002/jps.24242

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  40 in total

1.  Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.

Authors:  E D Breen; J G Curley; D E Overcashier; C C Hsu; S J Shire
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

Review 2.  Rational design of stable lyophilized protein formulations: theory and practice.

Authors:  John F Carpenter; Beyong S Chang; William Garzon-Rodriguez; Theodore W Randolph
Journal:  Pharm Biotechnol       Date:  2002

Review 3.  Lyophilization and development of solid protein pharmaceuticals.

Authors:  W Wang
Journal:  Int J Pharm       Date:  2000-08-10       Impact factor: 5.875

Review 4.  Design of freeze-drying processes for pharmaceuticals: practical advice.

Authors:  Xiaolin Tang; Michael J Pikal
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

5.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

6.  The effect of freeze-drying parameters and formulation composition on IgG stability during drying.

Authors:  V P Heljo; H Harju; T Hatanpää; G Yohannes; A M Juppo
Journal:  Eur J Pharm Biopharm       Date:  2013-04-24       Impact factor: 5.571

7.  Effects of buffer composition and processing conditions on aggregation of bovine IgG during freeze-drying.

Authors:  J M Sarciaux; S Mansour; M J Hageman; S L Nail
Journal:  J Pharm Sci       Date:  1999-12       Impact factor: 3.534

8.  The effects of Tween 20 and sucrose on the stability of anti-L-selectin during lyophilization and reconstitution.

Authors:  L S Jones; T W Randolph; U Kohnert; A Papadimitriou; G Winter; M L Hagmann; M C Manning; J F Carpenter
Journal:  J Pharm Sci       Date:  2001-10       Impact factor: 3.534

9.  A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.

Authors:  Serena D Webb; Jeffrey L Cleland; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2002-02       Impact factor: 3.534

10.  Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations.

Authors:  James D Andya; Chung C Hsu; Steven J Shire
Journal:  AAPS PharmSci       Date:  2003
View more
  5 in total

Review 1.  Pharmaceutical protein solids: Drying technology, solid-state characterization and stability.

Authors:  Yuan Chen; Tarun Tejasvi Mutukuri; Nathan E Wilson; Qi Tony Zhou
Journal:  Adv Drug Deliv Rev       Date:  2021-03-08       Impact factor: 15.470

2.  Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.

Authors:  Alexander M Faschinger; Nicole Sessler
Journal:  Adv Ther       Date:  2019-05-28       Impact factor: 3.845

3.  The effect of temperature exposure during shipment on a commercially available demineralized bone matrix putty.

Authors:  Mark Schallenberger; Helena Lovick; Jalane Locke; Todd Meyer; Gregory Juda
Journal:  Cell Tissue Bank       Date:  2016-08-25       Impact factor: 1.522

4.  AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG.

Authors:  Yukako Senga; Hiroshi Imamura; Takamitsu Miyafusa; Hideki Watanabe; Shinya Honda
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

5.  Aggregates Associated with Instability of Antibodies during Aerosolization Induce Adverse Immunological Effects.

Authors:  Thomas Sécher; Elsa Bodier-Montagutelli; Christelle Parent; Laura Bouvart; Mélanie Cortes; Marion Ferreira; Ronan MacLoughlin; Guy Ilango; Otmar Schmid; Renaud Respaud; Nathalie Heuzé-Vourc'h
Journal:  Pharmaceutics       Date:  2022-03-18       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.